Monthly Archives: April 2008

Stupak and Dingell “Concerned” May Spell Additional Reforms

On Friday, April 11, the House Committee on Energy and Commerce issued a release entitled "After Review of ENHANCE Trial Documents, Dingell, Stupak Express "Serious Concerns"" after writing to the CEOs of Merck and Schering Plough to ask for additional … Continue reading

Posted in Current Affairs, Legislation | Comments Off on Stupak and Dingell “Concerned” May Spell Additional Reforms

Weekly Roundup – 04/11/08

Well, Congress is back and writing enough letters to the stakeholders in the pharmaceutical industry to keep the Post Office in the black for many months!  The cherry blossoms have peaked and we have settled into several days of gloomy … Continue reading

Posted in Weekly Roundup | 1 Comment

A Signal for the Future on Intellectual Property?

Congressman Henry Waxman (D-CA), through the House Committee on Oversight and Reform, sent a letter to Susan C. Schwab, the U.S. Trade Representative yesterday that urged her to focus on access to medicines for those treatments that were life-saving weighing … Continue reading

Posted in Intellectual Property | Comments Off on A Signal for the Future on Intellectual Property?

Warning Letter Summary – First Quarter 2008

For some time, I have been writing about the lack of enforcement coming out of FDA in general and the Division of Drug Marketing and Advertising and Communications (DDMAC).  Well, DDMAC has hit a new low.  In looking at warning … Continue reading

Posted in Warning Letters | Comments Off on Warning Letter Summary – First Quarter 2008

More DTC Reforms

Yesterday I noted that there were letters flowing down from the Hill to manufacturers regarding some specific examples of Direct-to-Consumer (DTC) ads that were of interest to various members for various reasons.  Today, the Los Angeles Times carries a report … Continue reading

Posted in DTC Advertising | Comments Off on More DTC Reforms